Source: WESTLAKE VILLAGE, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed in the Company’s first-in-human, Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of psoriasis and the associated pruritus, or itch. SNA-125 is…...
QFR Solutions Earns Another Top Spot
Source: LinkedIn QFR Solutions has earned another Top spot in LinkedIn’s Top 25 Most Socially Engaged Staffing Agencies. This is the second top spot for QFR Solutions since the inception of the awards in 2016. QFR ranked #2 in 2017 and #1 in 2016. There were nearly 30,000 firms considered…...
Celgene’s $7 Billion Purchase Is Great For Drug Inventors. Is It Great For Celgene?
Source: Forbes Last night, Celgene announced that it is buying Impact BioMedicines, a small biotech developing a drug to compete with the blockbuster blood cancer drug Jakafi, sold by Incyte and Novartis, in an announcement timed to coincide with the annual J.P. Morgan Health Care Conference, where Celgene, as it…...